Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.91 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL25307085 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL14742964 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL3165960 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL24914 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL3165957 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL1336519 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL7804043 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL2670537 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL10390162 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL629997 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108740961-A | Low sodium delicate flavour salt of a kind of no bitter taste and preparation method thereof | 益盐堂（应城）健康盐制盐有限公司 | 2018-11-06 | — | — | CN | claimed |
| EP-1461006-B1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLUORIDE | PROCTER & GAMBLE (US) | 2016-09-28 | — | — | EP | claimed |
| EP-2069459-A1 | METHODS AND COMPOSITIONS RELATING TO THE CONTROL OF THE RATES OF ACID-GENERATING COMPOUNDS IN ACIDIZING OPERATIONS | Halliburton Energy Services, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| CN-100386065-C | Stable oral compositions comprising casein phosphopeptide complexes and flouride | PROCTER & GAMBLE (US) | 2008-05-07 | — | — | CN | claimed |
| WO-2008038033-A1 | METHODS AND COMPOSITIONS RELATING TO THE CONTROL OF THE RATES OF ACID-GENERATING COMPOUNDS IN ACIDIZING OPERATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| CN-1610535-A | Stable oral compositions comprising casein phosphopeptide complexes and flouride | PROCTER & GAMBLE (US) | 2005-04-27 | — | — | CN | claimed |
| US-6863882-B2 | Stable oral compositions comprising casein phosphopeptide complexes and fluoride | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-08 | — | — | US | claimed |
| EP-1461006-A1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLOURIDE | The Procter & Gamble Company (US) | 2004-09-29 | — | — | EP | claimed |
| WO-2003059304-A1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLOURIDE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| US-20030124066-A1 | Stable oral compositions comprising casein phosphopeptide complexes and fluoride | PROCTER AND GAMBLE COMPANY, THE | 2003-07-03 | — | — | US | claimed |
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | claimed |
| US-4720332-A | ZWITTERION, OXIDIZER | COFFEY BARRY W (US) | 1988-01-19 | — | — | US | claimed |
| US-12544349-B1 | Compositions comprising pemvidutide and an acylated amino acid | ADOCIA (FR) | 2026-02-10 | — | — | US | disclosed |
| US-20250387340-A1 | COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-12-25 | — | — | US | disclosed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-4648983-A | NONSETTLING | COLGATE-PALMOLIVE COMPANY (US) | 1987-03-10 | — | — | US | disclosed |
| US-4514431-A | LACTIC ACID AND/OR THE POTASSIUM SALT, A POTASSIUM COMPOUND AND A POTASSIUM HALIDE | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1985-04-30 | — | — | US | disclosed |
| US-4514094-A | APPARATUS USING ELECTRONIC PROGRAM CONTROL | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1985-04-30 | — | — | US | disclosed |
| US-4471002-A | PHOSPHATES, POTASSIUM AND SODIUM COMPOUNDS, LACTIC ACID | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TSHR 3844/4885TP53 4560/4885CYP2C9 1033/4885 |
| US-12544349-B1 | Compositions comprising pemvidutide and an acylated amino acid | SLC6A19, SLC1A5, ASNS | TSHR 1423/4885TP53 3618/4885CYP2C9 535/4885 |
| US-20250387340-A1 | COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPR1, NPPA, SLC7A1 | TSHR 875/4885TP53 2045/4885CYP2C9 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.